Asia
Akili receives upfront payments totalling $20 million and has the potential to receive milestone payments for Japan and Taiwan commercialisation of up to an additional $105 million, in addition to substantial royalties on product sales
Eisai Co., Ltd. has announced that a marketing authorization application has been submitted in Japan for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for use in the treatment of insomnia disorder.
Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
New medical center to offer an array of specialties and super specialties with in-house support for physiotherapy, radiology & ultrasound services
On Friday, the FDA raised concerns about losartan potassium tablets sold by India-based Hetero Labs Ltd. and distributed by Camber Pharmaceuticals.
Todos Medical Ltd., a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced that it has raised $1,350,500 from private investors.
Abpro, based in Woburn, Mass., inked a deal worth up to $4 billion with China-based Nanjing Chia Tai Tianqing Pharmaceutical Company, known as NJCTTQ, a global pharmaceutical company.
CRISPR, the gene editing technique that promises to revolutionize healthcare and medicine, is not perfect. Two new studies, one in mice embryos and the other in rice plants, seem to confirm this.
PRESS RELEASES